References
- Alkhatib NS, Erstad B, Ramos K, et al. Pricing methods in outcome-based contracting-δ1: cost-effectiveness analysis and cost utility analysis-based pricing. J Med Econ. 2020;23(11):1215–1222.
- Alkhatib NS, Ramos K, Erstad B, et al. Pricing methods in outcome-based contracting-δ2: willingness-to-pay-based pricing. J Med Econ. 2020;23(11):1223–1229.
- World Health Organization. WHO guideline on country pharmaceutical pricing policies. [cited Dec 2019]. Available from: https://apps.who.int/medicinedocs/documents/s21016en/s21016en.pdf
- Kanavos P, Ferrario A, Vandoros S, et al. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Aff (Millwood). 2013;32(4):753–761.
- Sarnak DO, Squires D, Bishop S. Paying for prescription drugs around the world: why is the U.S. an outlier. [cited December 2019]. Available from: https://www.commonwealthfund.org/publications/issue-briefs/2017/oct/paying-prescription-drugs-around-world-why-us-outlier
- Centers for Medicare and Medicaid Services. Medicare program: international pricing index model for Medicare part B drugs. [cited December 2019]. Available from: https://www.cms.gov/sites/drupal/files/2018-10/10-25-2018%20CMS-5528-ANPRM.PDF
- The Organization for Economic Co-operation and Development. [cited December 2019]. Available from: https://www.oecd.org
- Stargardt T, Schreyögg J. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation. Appl Health Econ Health Policy. 2006;5(4):235–247.
- U.S. Bureau of Labor Statistics. Prescription drugs in U.S. city average, all urban consumers, seasonally adjusted. [cited December 2019]. Available from: https://data.bls.gov/timeseries/CUSR0000SEMF01?output_view=pct_3mths
- Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. New York (NY): Oxford University Press; 2011.
- Soria J, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. N Engl J Med. 2018;378(2):113–125.
- RedBook Online [subscription database onlie]. Greenwood Village (CO): Truven Health Analytics, Inc. updated periodically. 2019 [cited December 2019]. Available from: http://micromedex.com/products/product-suites/clinical-knowledge/redbook
- Bertranou E, Bodnar C, Dansk V, et al. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. J Med Econ. 2018;21(2):113–121.
- Ezeife DA, Kirk V, Chew DS, et al. Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. Lung Cancer. 2018; 125:1–7.
- National Institute for Health and Care Excellence. Osimertinib for untreated EGFR-positive non-small-cell lung cancer [ID1302]. [cited December 2019]. Available from: https://www.nice.org.uk/consultations/528/1/recommendations
- Pan-Canadian Oncology Drug Review Final Clinical Guidance Report. Osimertinib (Tagrisso) for non-small cell lung cancer. [cited December 2019]. Available from: https://cadth.ca/sites/default/files/pcodr/Reviews2019/10137OsimertinibNSCLC_fnCGR_NOREDACT_Post_04Jan2019_final.pdf
- U.S. Department of Health and Human Services. Comparison of U.S. and international prices for top Medicare part B drug by total expenditures. [cited December 2019]. Available from: https://aspe.hhs.gov/system/files/pdf/259996/ComparisonUSInternationalPricesTopSpendingPartBDrugs.pdf